Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades3
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Pharmaceuticals shares boosted by positive data on cancer drug
22 Mar 2021 - UK earnings, trading statements calendar - next 7 days
18 Mar 2021 - Faron Pharmaceuticals Raises EUR15 Million In Share Placing
12 Feb 2021 - IN BRIEF: Faron Pharmaceuticals Plans To Raise EUR15 Million
11 Feb 2021 - IN BRIEF: Faron Pharmaceuticals Gets US Approval For Covid-19 Trial
26 Jan 2021 - Faron Notes "Remarkable" Observations From Bexmarilimab Trial
20 Jan 2021 - LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
20 Jan 2021 - LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts
18 Jan 2021
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Pharmaceuticals shares boosted by positive data on cancer drug
Faron Pharmaceuticals shares boosted by positive data on cancer drug
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Faron Pharmaceuticals Raises EUR15 Million In Share Placing
Faron Pharmaceuticals Raises EUR15 Million In Share Placing
IN BRIEF: Faron Pharmaceuticals Plans To Raise EUR15 Million
IN BRIEF: Faron Pharmaceuticals Plans To Raise EUR15 Million
IN BRIEF: Faron Pharmaceuticals Gets US Approval For Covid-19 Trial
IN BRIEF: Faron Pharmaceuticals Gets US Approval For Covid-19 Trial
Faron Notes "Remarkable" Observations From Bexmarilimab Trial
Faron Notes "Remarkable" Observations From Bexmarilimab Trial
LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal
LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts
LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts
Follow the stocks
